About
Clarenta is a European contract research organization supporting biotech and pharmaceutical companies through non-clinical development, CMC development, early-phase clinical research and full-service clinical trial delivery. It works with sponsors across Europe and has an early-phase unit in Sofia, with non-clinical and regulatory expertise also based in France through Leads To Development. The group says it supports clinical development across 24 countries.
Services
Clinical Research Consulting
Advises on development strategy, non-clinical inputs, regulatory strategy, trial design and clinical operations before a protocol is written.
Full-service CRO
Plans and delivers clinical trials across Europe, including clinical operations, project management, regulatory affairs, medical oversight, data management, biostatistics and pharmacovigilance.
Phase I Unit
Supports early clinical studies in healthy volunteers and patients from an on-site unit in Sofia with an on-site pharmacy and clinical laboratory.
Strategic Non-clinical Planning
Builds a non-clinical development plan covering study sequence, regulatory steps, manufacturing requirements and gaps to clinical milestones.
Non-clinical Development
Selects and manages GLP-compliant CROs, reviews protocols and reports, audits service providers and coordinates toxicology and pharmacology studies.
CMC Development
Plans chemistry, manufacturing and control work including process development, scale-up, analytical methods, formulation, stability and GMP or non-GMP manufacturing.
Early-stage Regulatory Affairs
Supports early regulatory strategy, scientific advice, pre-IND meetings, orphan drug or fast-track designations, CTA or IND applications and agency responses.
Early Phase Clinical Development
Supports early clinical development from first-in-human studies through proof-of-concept and PK/clinical pharmacology studies.
4 more services
- Early Phase Oncology Trials
- First-in-Human (FIH) Studies
- Proof-of-Concept (PoC) Studies
- PK & Clinical Pharmacology Studies
- Turnaround
- 36 patients enrolled within approximately two months
- 48 participants enrolled
- What to send
- Sample collection and processing
- Bioanalytical assay readiness
Capabilities
- Assays and studies
- Bioanalysis
- Pharmacokinetic sampling
- Bioanalytical assays
- Safety assessments
- Tolerability assessments
- Pharmacodynamic assessments
5 more
- Biomarker assessments
- Clinical monitoring
- Analytical testing
- Potency assays
- Bioanalytical methods
- Scale and capacity
- 1 Phase I unit
- 24 countries covered
- Therapeutic areas
- Oncology
- Onco-haematology
- Rare diseases
- Neurology
- Psychiatry
- Immunology
14 more
- Respiratory diseases
- Nephrology
- Gastroenterology
- Hepatology
- Dermatology
- Asthma
- Hematology
- Cardiology
- Orthopedics
- Rheumatology
- Urology
- Vaccinology
- Diabetes and metabolism
- Virology
Instruments and platforms
- eCRF
Modalities and species
- Modalities
- Small molecule
- Species and models
- Healthy volunteers
- Patients
- Specialist populations
- GLP-compliant CROs
Certifications
As the company states them, with the certificate or registry record where there is one.
ISO 9001:2015Self-reported
GLPSelf-reported
Industries served
- Biotech
- Pharmaceutical
- Medical device
- Combination product
Company
- Type
- CRO
- Founded
- 1997
- Quality
- ISO 9001:2015 · GCLP Accreditation · FDA Letter 2024 · FDA NAI Letters 2020 · FDA NAI Letters 2007
Locations
- Based in
- Sofia, Bulgaria
- Sites
- Paris, France
- London, UK
- Serves
- Europe, Central and Eastern Europe, 24 countries covered